Biotech Startups

Gut microbiome mapping for better medicines

2 investors

Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination. The company's pipeline focuses on treatments for viral infections and associated diseases as well as other refractory conditions.

2 investors

Precigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.

2 investors

PreciseDx develops molecular pathology diagnostic tools for cancer care, combining anatomical pathology with molecular and systems biology to enable precise diagnosis and treatment planning. The company's flagship product serves pathologists and oncologists seeking data-driven insights for patient risk stratification and personalized cancer care.

2 investors

PrecisionLife uses advanced AI and analytics to identify the biological mechanisms underlying complex chronic diseases, enabling earlier diagnosis and more personalized treatment selection. The company develops diagnostic tests, clinical tools, and insights for pharmaceutical and healthcare partners to improve disease understanding and patient outcomes across multiple therapeutic areas.

2 investors

PreComb is a Swiss biotech company developing its proprietary 3DTwin technology, which combines automated drug testing on patient-derived tumor twins with AI-guided data analysis and response prediction. The technology is designed for use in the clinic to support evidence-based, personalized treatment decisions in oncology.

2 investors

Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.

2 investors

Predictably Human is developing NoMore, an adaptive drug delivery device paired with a personalized digital companion, aimed at patients with mental health conditions, addiction, and other complex disorders. The system is intended to support an ecosystem of digital products and services around treatment.

2 investors

Predictiv Care uses DNA and genomic analysis to identify genetic predispositions so diseases can be predicted and prevented, with a focus on personalized, preventive health. The company aims to make precision and preventive healthcare affordable and understandable for individuals.

2 investors

Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).

2 investors

PreludeDx develops precision diagnostic tests for breast cancer to help physicians make informed treatment decisions and improve patient outcomes. The company serves oncologists, breast surgeons, and pathologists requiring molecular diagnostics for DCIS and other breast cancer subtypes.

2 investors

Prenostics develops a blood test to detect the earliest stages of cancer (stages 0-2), earlier than current methods, aiming to enable curative treatment. Its initial clinical targets are women at elevated risk of ovarian cancer and people with indeterminate lung nodules.

2 investors

Presentient develops BRAKES, a data science platform that analyzes clinical trial data using automation in secure enclaves to maintain blinding while enabling interim analyses, potentially reducing trial duration by up to 50% and identifying failing trials early.

2 investors

Preventive.bio focuses on preventing disease before birth. The page provides no further detail about its products, technology, or customers.

2 investors

Prima Mente is an AI biology company that generates its own data and builds general-purpose biological foundation models to translate discoveries into research and clinical outcomes, with an initial focus on understanding and protecting the brain from neurological disease. Its team of AI researchers, experimentalists, clinicians, and operators operates across London, San Francisco, and the UAE.

2 investors

Primex Pharmaceuticals owns and markets specialty anaesthetic pharmaceuticals for perioperative therapy on a global basis. The company acquires rights to established drug candidates and manages regulatory affairs and distribution without conducting internal R&D or manufacturing.

2 investors

Primrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.

2 investors

PrismBio develops biotech-derived colorants grown through fermentation of photosynthetic bacteria for use in food, beverages, and consumer products. The company produces natural, customizable pigments as sustainable alternatives to petrochemical-based dyes.

2 investors

ProFound Therapeutics discovers and develops therapeutic candidates by analyzing the expanded human proteome, identifying novel proteins from previously uncharacterized genetic sequences that can serve as drug targets for cancer, immune disorders, and metabolic diseases.

2 investors

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

2 investors

Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.

2 investors

Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals. Its lead program, PLX-821 (semaglutide), and broader pipeline of dual/triple agonists, amylin-based, and combination therapies are built on this half-life extension delivery architecture.

2 investors

2 investors

ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.

2 investors